Mendelian randomization reveals the risk association between lipid‐lowering drugs and digestive tract cancers; HMGCR inhibitors and NPC1L1 may be potentially associated with the risk of hepatocellular carcinoma and gastric cancer; This study provides some evidence for the clinical application of lipid‐lowering drugs. This evidence concerns the gene HMGCR and hepatocellular carcinoma.